ZOUNDESSA — 2349717
Application number
2349717
Registration number
TMA1340900
Type(s)
Standard Characters
Category
Trademark
CIPO Status
REGISTERED
TM5 status
LIVE/REGISTRATION/Issued
and Active
The trademark application has been registered with the Office.
Filed
2024-09-13
Registered
2025-08-15
Registration Expiry Date
2035-08-15
Registered Owner
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, IN 46285
UNITED STATES OF AMERICA
Agent
BORDEN LADNER GERVAIS LLP
World Exchange Plaza
100 Queen Street, Suite 1300
Ottawa
ONTARIO K1P1J9
Documents
Index headings
- ZOUNDESSA
Goods (Nice class & Statement)
- 5
- (1) Pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for the prevention and treatment of cardiovascular diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of metabolic diseases and disorders, namely diabetes, gout, arthritis and anemia; pharmaceutical preparations for the prevention and treatment of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for the treatment and prevention of migraines, headaches and pain; pharmaceutical preparations for the treatment and the prevention of dementia; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely dermatitis, skin and bacterial skin infections and fungal skin infections ; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema, and sexually transmitted diseases; pharmaceutical preparations for the treatment of digestive diseases and disorders, namely, Crohn's disease, irritable bowel syndrome; pharmaceutical preparations for the treatment of digestive diseases and disorders, namely, ulcerative colitis; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders, and neuromuscular diseases, namely primary periodic paralysis; pharmaceutical preparations for the treatment of endocrine diseases, namely, glucagonoma; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of immunologic diseases and disorders namely, autoimmune diseases and disorders; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical preparations for the treatment of mental health disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of metabolic disorders, namely diabetes, bulimia nervosa, anorexia, obesity and hypothyroidism; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of musculoskeletal disorders; pharmaceutical preparations for the treatment of neurological diseases, namely, Alzheimer's, Huntington's Disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological diseases, namely, myasthenia gravis; pharmaceutical preparations for the treatment of neurological diseases, namely, myasthenia gravis, Alzheimer's, Huntington's Disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for the treatment of Parkinson's disease; pharmaceutical preparations for the treatment of the central nervous system, namely, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease; pharmaceutical preparations for the treatment of vascular diseases; pharmaceutical preparations for treatment of coronavirus;
Claims
- Priority Filing Date: April 25, 2024, Country or Office: UNITED STATES OF AMERICA, Application No. 98519677 in association with the same kind of goods
Action History
| Action | Action date | Due date | Comments |
|---|---|---|---|
| Filed | 2024-09-13 | ||
| Created | 2024-09-13 | ||
| Formalized | 2024-09-13 | ||
| Pre-Assessment Letter Sent | 2024-09-26 | Goods or Services Not Acceptable | |
| Search Recorded | 2025-03-14 | ||
| Approved | 2025-03-24 | APPROVED BY PROGRAM EX200M1 | |
| Approval Notice Sent | 2025-03-24 | APPROVED BY PROGRAM EX200M1 | |
| Advertised | 2025-05-28 | Vol.72 Issue 3683 | |
| Registration Pending | 2025-08-15 | ||
| Registered | 2025-08-15 | 2035-08-15 |